PDF herunterladen
TumorDiagnostik & Therapie 2018; 39(03): 180-186
DOI: 10.1055/a-0574-4866
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York

Die personalisierte Therapie beim Ovarialkarzinom

 
Ann-K. Langner   *
Abteilung für Gynäkologie und gynäkologische Onkologie, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung
,
Nina F. Pauly   *
Abteilung für Gynäkologie und gynäkologische Onkologie, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung
,
Beyhan Ataseven
Abteilung für Gynäkologie und gynäkologische Onkologie, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung
,
Andreas du Bois
Abteilung für Gynäkologie und gynäkologische Onkologie, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. April 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die Behandlung des epithelialen Ovarial-, Tuben- und Peritonealkarzinoms (epithelial ovarian cancer; EOC) fußt auf 3 Säulen, die in unterschiedlichem Maße individualisierte bzw. personalisierte Medizin inkludieren:

  1. Die Operation, die immer personalisiert, d. h. angepasst an den Allgemeinzustand und die Reserven der Patientin, sowie individualisiert, d. h. adaptiert an das Tumorwachstum und Befallsmuster, durchgeführt wird.

  2. Die Chemotherapie, die bis dato nicht individualisiert bezüglich der Tumorbiologie, wohl aber angepasst an die klinische Situation zumindest in der Rezidivtherapie unter verschiedenen Regimen, wie z. B. platin- und nicht platinhaltig, ausgewählt wird.

  3. Die neueren zielgerichteten Substanzen, mit denen noch mehr Hoffnung auf personalisierte Medizin sowie effektivere und nebenwirkungsärmere Therapieregime für die individuelle Patientin verbunden wird.

* Beide Autorinnen waren zu gleichen Teilen beteiligt.


 

  • Literatur

  • 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland; Robert Koch-Institut. Krebs in Deutschland 2011/2012. Berlin: 2015. 10. Ausgabe
    Google Scholar
  • 2 Leitlinienprogramm Onkologie (DGK, DGGG, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (Langversion). Version 2.0 – Oktober 2016. AWMF-Registernummer: 032/035OL. Online: www.awmf.org/leitlinien/detailII/032-035OL.html Stand: 14.07.2017
    PubMedGoogle Scholar
  • 3 Harter P, Hauke J, Heitz F. et al. Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarial cancer (OC) patients (AGO TR-1). J Clin Oncol 2016 (Suppl.): Abstr. 5538 34.
    PubMedGoogle Scholar
  • 4 Deutsches Konsortium familiärer Brust- und Eierstockkrebs. Informationen. Online: http://www.konsortium-familiaererbrustkrebs.de/informationen/familiaererbrust-und-eierstockkrebs/ Stand: 14.07.2017
    PubMedGoogle Scholar
  • 5 Trimbos B, Timmers P, Pecorelli S. et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010; 102: 982-987
    CrossrefPubMedGoogle Scholar
  • 6 du Bois A, Reuss A, Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009; 115: 1234-1244
    CrossrefPubMedGoogle Scholar
  • 7 du Bois A, Luck HJ, Meier W. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329
    CrossrefPubMedGoogle Scholar
  • 8 Harter P, Sehouli J, Lorusso D. et al. LION: Lymphadenectomy in ovarian neoplasms–A prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 2017; 35: 5500-5500
    CrossrefPubMedGoogle Scholar
  • 9 Vergote I, Trope CG, Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953
    CrossrefPubMedGoogle Scholar
  • 10 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-257
    CrossrefPubMedGoogle Scholar
  • 11 Marth C, Zeimet A, Du Bois A. Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery?. Oncology Williston Park 2011; 25: 940-942 , 944
    PubMedGoogle Scholar
  • 12 du Bois A, Marth C, Pfisterer J. et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer 2012; 22: 182-185
    CrossrefPubMedGoogle Scholar
  • 13 Fotopoulou C, Sehouli J, Aletti G. et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol 2017; 35: 587-590
    PubMedGoogle Scholar
  • 14 ClinicalTrials.gov. Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST). Online: https://clinicaltrials.gov/ct2/show/NCT02828618 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 15 Perren TJ, Swart AM, Pfisterer J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496
    CrossrefPubMedGoogle Scholar
  • 16 Burger RA, Brady MF, Bookman MA. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483
    CrossrefPubMedGoogle Scholar
  • 17 du Bois A, Floquet A, Kim JW. et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014; 32: 3374-3382
    CrossrefPubMedGoogle Scholar
  • 18 du Bois A, Kristensen G, Ray-Coquard I. et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78-89
    CrossrefPubMedGoogle Scholar
  • 19 Grabowski JP, Harter P, Heitz F. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 2016; 140: 457-462
    CrossrefPubMedGoogle Scholar
  • 20 Gershenson DM, Bodurka DC, Coleman RL. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017; 35: 1103-1111
    CrossrefPubMedGoogle Scholar
  • 21 Okamoto A, Sugiyama T, Hamano T. et al. Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. J Clin Oncol 2014; 32: 5507-5507
    CrossrefPubMedGoogle Scholar
  • 22 Gore ME, Hackshaw A, Brady WE. et al. Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). J Clin Oncol 2015; 33: 5528-5528
    CrossrefPubMedGoogle Scholar
  • 23 Wilson MK, Pujade-Lauraine E, Aoki D. et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 2017; 28: 727-732
    CrossrefPubMedGoogle Scholar
  • 24 Harter P, Hahmann M, Lueck HJ. et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009; 16: 1324-1330
    CrossrefPubMedGoogle Scholar
  • 25 Harter P, Sehouli J, Reuss A. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21: 289-295
    CrossrefPubMedGoogle Scholar
  • 26 du Bois A, Vergote I, Ferron G. et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35: 5501-5501
    CrossrefPubMedGoogle Scholar
  • 27 Aghajanian C, Blank SV, Goff BA. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045
    CrossrefPubMedGoogle Scholar
  • 28 Pujade-Lauraine E, Hilpert F, Weber B. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302-1308
    CrossrefPubMedGoogle Scholar
  • 29 Ledermann J, Harter P, Gourley C. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392
    CrossrefPubMedGoogle Scholar
  • 30 Ledermann JA, Harter P, Gourley C. et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016; 17: 1579-1589
    CrossrefPubMedGoogle Scholar
  • 31 Pujade-Lauraine E, Ledermann J, Selle F. et al. Olaparib tablets as maintenace therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/NGOT-Ov21): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet Oncol 2017 Online: http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(17)30469-2.pdf Stand: 17.08.2017
    PubMedGoogle Scholar
  • 32 http://www.nasdaq.com. Clovis Oncologyʼs Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial. Online: http://www.nasdaq.com/press-release/clovisoncologys-rucaparib-significantlyimprovedprogression-free-survival-in-allovariancancer-20170619-00122 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 33 Mirza MR, Monk BJ, Herrstedt J. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375: 2154-2164
    CrossrefPubMedGoogle Scholar
  • 34 ClinicalTrials.gov. Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Online: https://clinicaltrials.gov/show/NCT02477644 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 35 ClinicalTrials.gov. A study of niraparib maintenance treatment in patients With advanced ovarian cancer following response on front-line platinum-based chemotherapy. Online: https://clinicaltrials.gov/ct2/show/NCT02655016 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 36 ClinicalTrials.gov. A study of atezolizumab versus placebo in combination With paclitaxel, carboplatin, and bevacizumab in participants with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer (IMagyn050). Online: https://clinicaltrials.gov/ct2/show/NCT03038100 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 37 ClinicalTrials.gov. ATALANTE: Atezolizumab vs placebo phase III study in late relapse ovarian cancer treated with chemotherapy + bevacizumab (ATALANTE). Online: https://clinicaltrials.gov/ct2/show/NCT02891824 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 38 ClinicalTrials.gov. A study to examine olaparib maintenance retreatment in patients with epithelial ovarian cancer (OReO). Online: https://clinicaltrials.gov/ct2/show/NCT02855944 Stand: 14.07.2017
    PubMedGoogle Scholar
  • 39 Liu JF, Barry WT, Birrer M. et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15: 1207-1214
    CrossrefPubMedGoogle Scholar
  • 40 Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22: 268-279
    CrossrefPubMedGoogle Scholar
  • 41 Swisher EM, Lin KK, Oza AM. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017; 18: 75-87
    CrossrefPubMedGoogle Scholar
  • 42 Ledermann J, Harter P, Gourley C. et al. Olaparib maintenance therapy in patients with platinum sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-861
    CrossrefPubMedGoogle Scholar